Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $1045
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas maintains a 'Buy' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) but lowers the price target from $1050 to $1045.
June 28, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' price target has been lowered from $1050 to $1045 by Truist Securities, though the 'Buy' rating is maintained.
The news of a lowered price target could potentially create some uncertainty among investors, possibly leading to short-term volatility in the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100